- US-listed companies
- CRISPR Therapeutics AG
- Income statement
CRISPR Therapeutics AGCRSP
Market cap
$4.8B
P/E ratio
| 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 5 | 41 | 3 | 290 | 1 | 915 | 1 | 371 | 37 |
| Revenue growth (%) | - | ||||||||
| Research & development | 42 | 70 | 114 | 179 | 267 | 439 | 462 | 387 | 321 |
| Operating margin (%) | |||||||||
| Operating income | -68 | -65 | -159 | 47 | -354 | 374 | -673 | -223 | -467 |
| Operating expenses | 73 | 106 | 162 | 243 | 355 | 541 | 674 | 594 | 504 |
| Income before tax | -23 | -67 | -164 | 67 | -348 | 380 | -650 | -151 | -363 |
| Pretax margin (%) | -439.9 | -162.5 | -5,263.4 | 23.2 | -48,408.3 | 41.5 | -54,298.8 | -40.6 | -971.9 |
| Provision for income taxes | 0 | 2 | 1 | 0 | 1 | 2 | -0 | 3 | 4 |
| Effective tax rate (%) | |||||||||
| Net income | -23 | -68 | -165 | 67 | -349 | 378 | -650 | -154 | -366 |
| Net income margin (%) | |||||||||
| Earnings per share | - | - | - | 1.23 | -5.29 | 4.97 | -8.36 | -1.94 | -4.34 |
| Diluted EPS | - | - | - | 1.17 | -5.29 | 4.7 | -8.36 | -1.94 | -4.34 |
| EBITDA | |||||||||
| EBITDA margin (%) |